Impact of HER2+ Ratio on efficacy of Trastuzumab in early Breast Cancer
LMJ-Lebanese Medical Journal. 2019; 67 (suppl.): 36
in English
| IMEMR
| ID: emr-206750
ABSTRACT
Background:
Human epidermal growth factor receptor 2 [HER2] is a significant predictive factor for benefit from adjuvant Trastuzumab [HER2-targeted therapy] which is considered the standard treatment for patients with HER2+ early breast cancer [EBC] after completion of adjuvant chemotherapy. We aimed to determine whether the high level of HER2 positivity would influence the outcome of adjuvant Trastuzumab and the prognosis at diagnosis
Search on Google
Index:
IMEMR (Eastern Mediterranean)
Language:
English
Journal:
Lebanese Med. J.
Year:
2019
Similar
MEDLINE
...
LILACS
LIS